Related Experiment Video
Updated: Nov 26, 2025
PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
Published on: December 28, 2017
Dynamic 18F-FDOPA-PET/MRI for the preoperative evaluation of gliomas: correlation with stereotactic histopathology
Maria R Ponisio1, Jonathan E McConathy2, Sonika M Dahiya3
1Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, Missouri.
Background:
MRI alone has limited accuracy for delineating tumor margins and poorly predicts the aggressiveness of gliomas, especially when tumors do not enhance. This study evaluated simultaneous 3,4-dihydroxy-6-[18F]fluoro-L-phenylalanine (FDOPA)-PET/MRI to define tumor volumes compared to MRI alone more accurately, assessed its role in patient management, and correlated PET findings with histopathology.
Methods:
Ten patients with known or suspected gliomas underwent standard of care surgical resection and/or stereotactic biopsy. FDOPA-PET/MRI was performed prior to surgery, allowing for precise co-registration of PET, MR, and biopsies. The biopsy sites were modeled as 5-mm spheres, and the local FDOPA uptake at each site was determined. Correlations were performed between measures of tumor histopathology, and static and dynamic PET values: standardized uptake values (SUVs), tumor to brain ratios, metabolic tumor volumes, and tracer kinetics at volumes of interest (VOIs) and biopsy sites.
Results:
Tumor FDOPA-PET uptake was visualized in 8 patients. In 2 patients, tracer uptake was similar to normal brain reference with no histological findings of malignancy. Eight biopsy sites confirmed for glioma had FDOPA uptake without T1 contrast enhancement. The PET parameters were highly correlated only with the cell proliferation marker, Ki-67 (SUVmax: r = 0.985, P = .002). In this study, no statistically significant difference between high-grade and low-grade tumors was demonstrated. The dynamic PET analysis of VOIs and biopsy sites showed decreasing time-activity curves patterns. FDOPA-PET imaging directly influenced patient management.
Conclusions:
Simultaneous FDOPA-PET/MRI allowed for more accurate visualization and delineation of gliomas, enabling more appropriate patient management and simplified validation of PET findings with histopathology.
Insights
Simultaneous 3,4-dihydroxy-6-[18F]fluoro-L-phenylalanine (FDOPA)-PET/MRI accurately visualizes gliomas, improving patient management. This advanced imaging correlates well with tumor cell proliferation, aiding in diagnosis when MRI alone is insufficient.
Area of Science:
- Neuro-oncology
- Radiology
- Nuclear Medicine
Background:
- MRI alone has limitations in accurately defining glioma tumor margins and predicting aggressiveness, especially for non-enhancing tumors.
- Accurate tumor delineation is crucial for effective treatment planning and patient management in neuro-oncology.
Purpose of the Study:
- To evaluate simultaneous 3,4-dihydroxy-6-[18F]fluoro-L-phenylalanine (FDOPA)-PET/MRI for more accurate glioma volume definition compared to MRI alone.
- To assess the role of FDOPA-PET/MRI in patient management and correlate PET findings with histopathology.
Main Methods:
- Ten patients with gliomas underwent FDOPA-PET/MRI prior to surgical resection or biopsy.
- Precise co-registration of PET, MR, and biopsy data was achieved.
- Correlations were performed between histopathology and static/dynamic PET parameters (SUVs, tumor-to-brain ratios, metabolic tumor volumes, tracer kinetics).
Main Results:
- FDOPA-PET/MRI visualized tumor uptake in 8 patients; 2 showed uptake similar to normal brain without malignancy.
- Eight biopsy-confirmed gliomas demonstrated FDOPA uptake without T1 contrast enhancement.
- PET parameters strongly correlated with the Ki-67 proliferation marker (SUVmax: r=0.985, P=.002); dynamic analysis showed decreasing time-activity curves.
Conclusions:
- Simultaneous FDOPA-PET/MRI provides more accurate glioma visualization and delineation.
- This integrated imaging approach facilitates appropriate patient management and simplifies the validation of PET findings with histopathology.
![Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F58641.jpg&w=3840&q=50)
